<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253370</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02951</org_study_id>
    <secondary_id>NCI-2012-02951</secondary_id>
    <secondary_id>E5203</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT00253370</nct_id>
  </id_info>
  <brief_title>Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving sorafenib together with docetaxel and
      cisplatin works in treating patients with metastatic or locally advanced gastric or
      gastroesophageal junction cancer that cannot be removed by surgery. Sorafenib may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking
      blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Giving sorafenib together with docetaxel and cisplatin may kill more
      tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the response rate (complete response and partial response) of the combination
      of BAY 43-9006 with docetaxel and cisplatin or oxaliplatin in patients with gastric and GEJ
      adenocarcinoma.

      II. To evaluate the progression-free survival (PFS) and overall survival.

      III. To evaluate the toxicities of BAY 43-9006 in patients with advanced and metastatic
      gastric or GEJ adenocarcinoma combined with docetaxel/cisplatin or docetaxel/oxaliplatin.

      IV. To evaluate Raf status in the tumor and to correlate response and PFS to the presence or
      absence of an activating mutation in B-Raf.

      V. To analyze the pharmacokinetic and pharmacogenetic properties of BAY 43-9006 including
      angiogenesis, monooxygenases, polymorphisms and multidrug-resistance (MDR). This study will
      be conducted via the E1Y03 mechanism.

      OUTLINE: This is an open-label, multicenter study. Patients are stratified according to
      Siewert's tumor location (I vs II vs III) and extent of disease (locally advanced
      unresectable vs distant metastases).

      Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel
      intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every
      21 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically for 3 years.

      An addition of an arm containing oxaliplatin was proposed after meeting the accrual goal but
      did not move forward and the study was closed to accrual in July, 2007 with a final accrual
      of 44 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Patients With Objective Response (Complete Response or Partial Response)</measure>
    <time_frame>Assessed every 6 weeks until disease progression or up to 3 years</time_frame>
    <description>Response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= &gt;=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Objective response = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Assessed every 6 weeks until disease progression or up to 3 years</time_frame>
    <description>Progression-free survival was defined as the shorter of:
The time from registration to progression. or
The time from registration to death without documentation of progression given that the death occurs within 4 months of the last disease assessment without progression (or registration, whichever is more recent).
Therefore, cases not meeting either of the criteria for a PFS event are censored at the date of last disease assessment without progression (or registration, whichever is more recent).
Progression is defined as at least 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed every 3 months if patient is &lt; 2 years from study entry; then every 6 months if patient is 2-3 years from study entry.</time_frame>
    <description>Overall survival was defined as the time from registration to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Metastatic Gastric Cancer</condition>
  <condition>Advanced Unresectable Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>BAY 43-9006, docetaxel, cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 43-9006</intervention_name>
    <description>Given orally</description>
    <arm_group_label>BAY 43-9006, docetaxel, cisplatin</arm_group_label>
    <other_name>Sorafenib (NSC724772)</other_name>
    <other_name>BAY 54-9085 (tosylate salt)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>BAY 43-9006, docetaxel, cisplatin</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>RP 56976</other_name>
    <other_name>NSC #628503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>BAY 43-9006, docetaxel, cisplatin</arm_group_label>
    <other_name>Cis-diaminedichloroplatinum</other_name>
    <other_name>Cis-diaminedichloroplatinum (II)</other_name>
    <other_name>diaminedichloroplatinum</other_name>
    <other_name>cis-platinum</other_name>
    <other_name>platinum</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>DDP</other_name>
    <other_name>CDDP</other_name>
    <other_name>DACP</other_name>
    <other_name>NSC 119875.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have measurable, histologically confirmed, advanced unresectable or
             metastatic gastric or GEJ adenocarcinoma; imaging studies must be conducted within 4
             weeks of study entry

          -  For patients with GEJ adenocarcinoma, the tumor location should be specified using the
             Siewert classification used in other NCI-sponsored Phase II studies in these disease
             sites

          -  Patients must have an ECOG performance status of 0-1

          -  Patients may have had adjuvant chemotherapy or chemoradiation therapy, with or without
             5-Fluorouracil if the treatment was performed more than 6 months before any evidence
             of recurrent or metastatic disease

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Must have the following baseline laboratory values obtained within 2 weeks of
             registration:

               -  Absolute Granulocyte Count &gt;= 1,500/mm^3

               -  Platelet Count &gt;= 100,000/mm^3

               -  White Blood Count &gt;= 3,000/mm^3

               -  Serum Creatinine &lt;= 1.5 mg/dl

               -  Total Bilirubin &lt;= 2.0 mg/dl

               -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/alkaline
                  phosphatase (Alk phos) &lt;= 2.5 x upper limit of normal

          -  Patients must be able to take oral medication without crushing, dissolving or chewing
             tablets

        Exclusion Criteria:

          -  Prior radiotherapy, chemotherapy or investigational therapies, particularly inhibitors
             of tyrosine Kinases, signal transduction or angiogenesis in the treatment for their
             recurrent and/or metastatic gastric or GEJ adenocarcinoma

          -  Receiving any other investigational agents

          -  Being pregnant or breast-feeding; all females of childbearing potential must have a
             blood or urine test within 2 weeks prior to registration to rule out pregnancy

          -  HIV-positive patients receiving combination antiretroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with BAY 43-9006

          -  Brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to BAY 43-9006

          -  Acute active infection with significant clinical intervention per physician's
             discretion

          -  Previous or concurrent malignancies are not allowed, except:

               -  Non-melanoma skin cancer and in situ cervical cancer

               -  Treated cancer from which the patient has been continuously disease-free for more
                  than five years

          -  Other uncontrolled intercurrent illnesses including, but not limited to: uncontrolled
             hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia or psychiatric illness/addictive disorders that would limit compliance with
             study requirements

          -  Evidence of bleeding diathesis

          -  Concurrent cytochrome P450 enzyme-inducing anti-epileptic drugs:

               -  Phenytoin

               -  Carbamazepine

               -  Phenobarbital

               -  Rifampin

               -  St. John's Wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijing Sun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010 Jun 20;28(18):2947-51. doi: 10.1200/JCO.2009.27.7988. Epub 2010 May 10.</citation>
    <PMID>20458043</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>May 21, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>gastroesophageal junction adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from ECOG member institutions between October 28, 2005 and July 2, 2007. The final accrual was 44 patients.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BAY 43-9006, Docetaxel, Cisplatin</title>
          <description>Patients receive oral BAY 43-9006 400 mg twice daily on days 1-21. Patients also receive docetaxel IV, 75mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abdominal pain due to disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 44 patients started treatment and were considered eligible and hence were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>BAY 43-9006, Docetaxel, Cisplatin</title>
          <description>Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" lower_limit="28.4" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Patients With Objective Response (Complete Response or Partial Response)</title>
        <description>Response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= &gt;=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Objective response = CR + PR.</description>
        <time_frame>Assessed every 6 weeks until disease progression or up to 3 years</time_frame>
        <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>BAY 43-9006, Docetaxel, Cisplatin</title>
            <description>Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Objective Response (Complete Response or Partial Response)</title>
          <description>Response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= &gt;=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Objective response = CR + PR.</description>
          <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.409" lower_limit="0.284" upper_limit="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The study was designed to distinguish a response rate of 40% from 20%, the null hypothesis. With the planned sample size of 36 eligible patients, the study has 91% power based on a 0.09 level one-sided test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>one-sample binomial test</method>
            <param_type>proportion of participants</param_type>
            <param_value>0.409</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.284</ci_lower_limit>
            <ci_upper_limit>0.544</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival was defined as the shorter of:
The time from registration to progression. or
The time from registration to death without documentation of progression given that the death occurs within 4 months of the last disease assessment without progression (or registration, whichever is more recent).
Therefore, cases not meeting either of the criteria for a PFS event are censored at the date of last disease assessment without progression (or registration, whichever is more recent).
Progression is defined as at least 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing non-target lesions.</description>
        <time_frame>Assessed every 6 weeks until disease progression or up to 3 years</time_frame>
        <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>BAY 43-9006, Docetaxel, Cisplatin</title>
            <description>Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival was defined as the shorter of:
The time from registration to progression. or
The time from registration to death without documentation of progression given that the death occurs within 4 months of the last disease assessment without progression (or registration, whichever is more recent).
Therefore, cases not meeting either of the criteria for a PFS event are censored at the date of last disease assessment without progression (or registration, whichever is more recent).
Progression is defined as at least 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing non-target lesions.</description>
          <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.4" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival was defined as the time from registration to death from any cause.</description>
        <time_frame>Assessed every 3 months if patient is &lt; 2 years from study entry; then every 6 months if patient is 2-3 years from study entry.</time_frame>
        <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>BAY 43-9006, Docetaxel, Cisplatin</title>
            <description>Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival was defined as the time from registration to death from any cause.</description>
          <population>All enrolled patients started treatment and were considered eligible and hence were all included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="8.6" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every 3 weeks while on treatment and for 30 days after the end of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BAY 43-9006, Docetaxel, Cisplatin</title>
          <description>Patients receive oral BAY 43-9006 twice daily on days 1-21. Patients also receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BAY 43-9006: Given orally
docetaxel: Given IV
cisplatin: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fistula, Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Stenosis (incl anastomotic) esophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Esophagus, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Esophagus, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/ gr3-4 neut, catheter relate</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection w/ gr3-4 neut, blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut, blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutrophils decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Platelets decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Scalp, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam, oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutrophils decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Platelets decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity-limb, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muscle, pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

